4 completed, 4 recruiting, 1 active not recruiting, 1 withdrawn. 4 Phase 1, 4 Phase 2, 3 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 2, Recruiting 2 |
| Phase 2 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Early Phase 1 | 3 | Recruiting 2, Completed 1 |
Follow AC Immune SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants and in Participants With Cardiovascular Risk Factors Placebo, ACI-19764 at dose A1, ACI-19764 at dose A2 - Healthy Participants, Obesity | Phase 1 | Recruiting | AC Immune SA | 114 | 2026-01-28 | 2026-09-02 |
| [18F]ACI-15916 PET in α-synucleinopathies [18F]ACI-15916 - Parkinson's Disease (PD), Multiple System Atrophy (MSA) | Early Phase 1 | Recruiting | AC Immune SA | 46 | 2025-03-20 | 2025-11-19 |
| [18F]ACI-19626 PET in TDP-43 Proteinopathies [18F]ACI-19626 - Frontotemporal Dementia (FTD), Amyotrophic Lateral Sclerosis (ALS) | Early Phase 1 | Recruiting | AC Immune SA | 45 | 2025-01-21 | 2026-08-26 |
| A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease Placebo, ACI-7104.056 at Dose A, ACI-7104.056 at Dose B (optional) - Parkinson Disease, Parkinson Disease 6, Early-Onset | Phase 2 | Active not recruiting | AC Immune SA | 150 | 2023-07-24 | 2026-10-01 |
| A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a - Amyloid Plaque, Beta-Amyloid | Phase 1 / Phase 2 | Recruiting | AC Immune SA | 304 | 2022-06-21 | 2026-07-10 |
| A Study of ACI-24 in Adults With Down Syndrome ACI-24, Placebo - Down Syndrome | Phase 2 | Withdrawn | AC Immune SA | 2021-10-01 | 2021-10-22 | |
| Optimization of Morphomer-based Alpha-synuclein PET Tracers Parkinson Disease, Dementia With Lewy Bodies | Completed | Skane University Hospital | 12 | 2021-07-15 | 2021-10-05 | |
| Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain [18F]MNI-1216 - Alpha-Synucleinopathy, Parkinson's Disease | Early Phase 1 | Completed | Invicro | 12 | 2020-12-24 | 2025-02-19 |
| A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease ACI-35.030, Placebo, JACI-35.054 - Alzheimer's Disease, Cognitive Impairment | Phase 1 / Phase 2 | Completed | AC Immune SA | 57 | 2019-07-31 | 2025-02-14 |
| Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome ACI-24 low dose, ACI-24 high dose, Placebo - Down Syndrome | Phase 1 | Completed | AC Immune SA | 20 | 2016-03-01 | 2021-10-15 |
Parkinson Disease (4) · Alzheimer Disease (3) · Cognitive Dysfunction (3) · Down Syndrome (3) · Lewy Body Disease (3) · Multiple System Atrophy (3) · Brain Diseases (2) · Central Nervous System Diseases (2) · Dementia (2) · Amyotrophic Lateral Sclerosis (1) · Corticobasal Degeneration (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Frontotemporal Dementia (1) · Obesity (1)
Netherlands (3) · Sweden (3) · United Kingdom (3) · United States (3) · Spain (2) · Finland (1) · Germany (1)
Michael S. Rafii, MD, PhD (2) · Andrea Varrone, Prof. (1) · Daniela Berg, Prof. (1) · David Russell, MD (1) · Elsmarieke van de Giessen, MD (1) · Michael Rafii, MD (1) · Oskar Hansson, Professor (1) · Philip Scheltens, MD (1)
2018 (1), 2025 (1), R01AG047922 (1)